"ENACT's research methodology mirrors our organizational role within YPPS
We create spaces where potential transforms into action, where diverse perspectives find common ground, and where emerging ideas are nurtured toward independence. Just as we incubate new research divisions within YPPS, our research process itself serves as an incubator for nascent ideas that might otherwise remain unexplored."
UAspire
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults with Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, and to characterize the durability of initial treatment effect and subsequent response to optional Psilocybin 25 mg re-administration(s) during the 1-year Follow-up Period.
Cohen
Effects of repeated dosing of psilocybin on obsessive-compulsive disorder: A randomized, waitlist-controlled study
This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD.
Open-Label
Safety, feasibility, and tolerability of psilocybin treatment for individuals with functional impairment related to mood, anxiety, trauma and/or addiction symptoms: An open-label proof-of-concept study.
The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The investigators will recruit individuals with mood, anxiety, trauma, addictive, or related symptomatology, and who have functional impairment associated with these symptoms. The investigators will allow for comorbidity and only exclude based on psychological and physiological safety considerations. Critically, this approach will allow us to assess the tolerability of our interventions in individuals who would typically be excluded from efficacy studies due to various comorbid DSM-5 conditions.
